D
Nektar Therapeutics
NKTR
$0.8968
$0.08149.98%
D
Sell
3/11/2025Upgraded
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 3/11/2025 due to an increase in the volatility index and valuation index.
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 3/11/2025 due to an increase in the volatility index and valuation index.
E
Sell
2/21/2025Downgrade
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 2/21/2025 due to a decline in the valuation index and total return index.
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 2/21/2025 due to a decline in the valuation index and total return index.
D
Sell
2/6/2025Upgraded
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 2/6/2025 due to an increase in the valuation index and growth index.
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 2/6/2025 due to an increase in the valuation index and growth index.
E
Sell
11/11/2024Downgrade
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 11/11/2024 due to a decline in the solvency index and valuation index. Debt to equity increased from 1.62 to 2.44, and the quick ratio declined from 4.78 to 3.65.
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 11/11/2024 due to a decline in the solvency index and valuation index. Debt to equity increased from 1.62 to 2.44, and the quick ratio declined from 4.78 to 3.65.
D
Sell
4/12/2024Upgraded
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 4/12/2024 due to a noticeable increase in the volatility index, total return index and growth index. EBIT increased 8.49% from -$33.5M to -$30.66M, and earnings per share increased from -$0.2407 to -$0.2211.
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 4/12/2024 due to a noticeable increase in the volatility index, total return index and growth index. EBIT increased 8.49% from -$33.5M to -$30.66M, and earnings per share increased from -$0.2407 to -$0.2211.
E
Sell
3/14/2023Downgrade
Nektar Therapeutics (NKTR) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
Nektar Therapeutics (NKTR) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/9/2023Upgraded
Nektar Therapeutics (NKTR) was upgraded to D from E+ on 02/09/2023.
Nektar Therapeutics (NKTR) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Nektar Therapeutics (NKTR) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
Nektar Therapeutics (NKTR) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
11/7/2022Upgraded
Nektar Therapeutics (NKTR) was upgraded to D from D- on 11/7/2022 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.8515 to -$0.3147, EBIT increased 19.92% from -$46.79M to -$37.47M, and total revenue increased 9.45% from $21.59M to $23.63M.
Nektar Therapeutics (NKTR) was upgraded to D from D- on 11/7/2022 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.8515 to -$0.3147, EBIT increased 19.92% from -$46.79M to -$37.47M, and total revenue increased 9.45% from $21.59M to $23.63M.
D
Sell
5/6/2022Upgraded
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 5/6/2022 due to a noticeable increase in the growth index. Operating cash flow increased 41.65% from -$151.54M to -$88.42M, and earnings per share increased from -$0.7874 to -$0.4864.
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 5/6/2022 due to a noticeable increase in the growth index. Operating cash flow increased 41.65% from -$151.54M to -$88.42M, and earnings per share increased from -$0.7874 to -$0.4864.
E
Sell
5/4/2022Downgrade
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 5/4/2022 due to a decline in the volatility index and total return index.
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 5/4/2022 due to a decline in the volatility index and total return index.
D
Sell
4/19/2022Upgraded
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 4/19/2022 due to an increase in the volatility index.
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 4/19/2022 due to an increase in the volatility index.
E
Sell
3/25/2022Downgrade
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 3/25/2022 due to a decline in the volatility index, total return index and growth index. Operating cash flow declined 49.84% from -$101.14M to -$151.54M, and earnings per share declined from -$0.7045 to -$0.7874.
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 3/25/2022 due to a decline in the volatility index, total return index and growth index. Operating cash flow declined 49.84% from -$101.14M to -$151.54M, and earnings per share declined from -$0.7045 to -$0.7874.
D
Sell
11/23/2021Upgraded
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 11/23/2021 due to an increase in the valuation index.
Nektar Therapeutics (NKTR) was upgraded to D- from E+ on 11/23/2021 due to an increase in the valuation index.
E
Sell
11/8/2021Downgrade
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 11/8/2021 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 22% from -$82.9M to -$101.14M, the quick ratio declined from 7.85 to 6.79, and total revenue declined 12.03% from $28.33M to $24.92M.
Nektar Therapeutics (NKTR) was downgraded to E+ from D- on 11/8/2021 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 22% from -$82.9M to -$101.14M, the quick ratio declined from 7.85 to 6.79, and total revenue declined 12.03% from $28.33M to $24.92M.
D
Sell
9/28/2021Downgrade
Nektar Therapeutics (NKTR) was downgraded to D- from D on 9/28/2021 due to a substantial decline in the growth index, solvency index and total return index. The quick ratio declined from 8.63 to 7.85, operating cash flow declined 7.54% from -$77.09M to -$82.9M, and earnings per share declined from -$0.678 to -$0.687.
Nektar Therapeutics (NKTR) was downgraded to D- from D on 9/28/2021 due to a substantial decline in the growth index, solvency index and total return index. The quick ratio declined from 8.63 to 7.85, operating cash flow declined 7.54% from -$77.09M to -$82.9M, and earnings per share declined from -$0.678 to -$0.687.
D
Sell
8/24/2020Downgrade
Nektar Therapeutics (NKTR) was downgraded to D from D+ on 8/24/2020 due to a decline in the volatility index and total return index.
Nektar Therapeutics (NKTR) was downgraded to D from D+ on 8/24/2020 due to a decline in the volatility index and total return index.
D
Sell
8/7/2020Upgraded
Nektar Therapeutics (NKTR) was upgraded to D+ from D on 8/7/2020 due to a significant increase in the growth index and valuation index. Earnings per share increased from -$0.7825 to -$0.4486, and EBIT increased 12.14% from -$88.44M to -$77.71M.
Nektar Therapeutics (NKTR) was upgraded to D+ from D on 8/7/2020 due to a significant increase in the growth index and valuation index. Earnings per share increased from -$0.7825 to -$0.4486, and EBIT increased 12.14% from -$88.44M to -$77.71M.
D
Sell
8/13/2019Downgrade
Nektar Therapeutics (NKTR) was downgraded to D from C- on 8/13/2019 due to a significant decline in the valuation index, growth index and efficiency index. Total revenue declined 17.39% from $28.22M to $23.32M, and total capital declined 3.74% from $1.98B to $1.9B.
Nektar Therapeutics (NKTR) was downgraded to D from C- on 8/13/2019 due to a significant decline in the valuation index, growth index and efficiency index. Total revenue declined 17.39% from $28.22M to $23.32M, and total capital declined 3.74% from $1.98B to $1.9B.
C
Hold
3/6/2019Upgraded
Nektar Therapeutics (NKTR) was upgraded to C- from D+ on 3/6/2019 due to a substantial increase in the growth index and efficiency index. Total revenue increased 43.46% from $27.76M to $39.83M.
Nektar Therapeutics (NKTR) was upgraded to C- from D+ on 3/6/2019 due to a substantial increase in the growth index and efficiency index. Total revenue increased 43.46% from $27.76M to $39.83M.
D
Sell
11/14/2018Upgraded
Nektar Therapeutics (NKTR) was upgraded to D+ from D- on 11/14/2018 due to a significant increase in the valuation index, solvency index and efficiency index.
Nektar Therapeutics (NKTR) was upgraded to D+ from D- on 11/14/2018 due to a significant increase in the valuation index, solvency index and efficiency index.
D
Sell
5/14/2018Downgrade
Nektar Therapeutics (NKTR) was downgraded to D- from D on 5/14/2018 due to a major decline in the total return index, growth index and efficiency index. EBIT declined 1,203.76% from -$6.65M to -$86.74M, net income declined 183.19% from -$33.83M to -$95.79M, and earnings per share declined from -$0.2137 to -$0.5954.
Nektar Therapeutics (NKTR) was downgraded to D- from D on 5/14/2018 due to a major decline in the total return index, growth index and efficiency index. EBIT declined 1,203.76% from -$6.65M to -$86.74M, net income declined 183.19% from -$33.83M to -$95.79M, and earnings per share declined from -$0.2137 to -$0.5954.
D
Sell
12/18/2017Upgraded
Nektar Therapeutics (NKTR) was upgraded to D from D- on 12/18/2017 due to an increase in the total return index, solvency index and volatility index.
Nektar Therapeutics (NKTR) was upgraded to D from D- on 12/18/2017 due to an increase in the total return index, solvency index and volatility index.
D
Sell
11/28/2017Downgrade
Nektar Therapeutics (NKTR) was downgraded to D- from D on 11/28/2017 due to a noticeable decline in the total return index and valuation index.
Nektar Therapeutics (NKTR) was downgraded to D- from D on 11/28/2017 due to a noticeable decline in the total return index and valuation index.
D
Sell
11/13/2017Upgraded
Nektar Therapeutics (NKTR) was upgraded to D from D- on 11/13/2017 due to a significant increase in the growth index, solvency index and total return index. Total revenue increased 342.13% from $34.59M to $152.93M, operating cash flow increased 259.04% from -$58.52M to $93.08M, and EBIT increased 246.73% from -$47.36M to $69.49M.
Nektar Therapeutics (NKTR) was upgraded to D from D- on 11/13/2017 due to a significant increase in the growth index, solvency index and total return index. Total revenue increased 342.13% from $34.59M to $152.93M, operating cash flow increased 259.04% from -$58.52M to $93.08M, and EBIT increased 246.73% from -$47.36M to $69.49M.
D
Sell
5/12/2017Downgrade
Nektar Therapeutics (NKTR) was downgraded to D- from D on 5/12/2017 due to a decline in the solvency index, valuation index and volatility index. Debt to equity increased from 2.8 to 5.52, and the quick ratio declined from 5.6 to 4.59.
Nektar Therapeutics (NKTR) was downgraded to D- from D on 5/12/2017 due to a decline in the solvency index, valuation index and volatility index. Debt to equity increased from 2.8 to 5.52, and the quick ratio declined from 5.6 to 4.59.
D
Sell
10/19/2016Upgraded
Nektar Therapeutics (NKTR) was upgraded to D from D- on 10/19/2016 due to an increase in the volatility index and valuation index.
Nektar Therapeutics (NKTR) was upgraded to D from D- on 10/19/2016 due to an increase in the volatility index and valuation index.
D
Sell
8/5/2016Downgrade
Nektar Therapeutics (NKTR) was downgraded to D- from D on 8/5/2016 due to a decline in the growth index, volatility index and valuation index. EBIT declined 304.1% from -$9.48M to -$38.33M, earnings per share declined from -$0.1436 to -$0.3565, and total revenue declined 44.35% from $58.88M to $32.77M.
Nektar Therapeutics (NKTR) was downgraded to D- from D on 8/5/2016 due to a decline in the growth index, volatility index and valuation index. EBIT declined 304.1% from -$9.48M to -$38.33M, earnings per share declined from -$0.1436 to -$0.3565, and total revenue declined 44.35% from $58.88M to $32.77M.
D
Sell
5/6/2016Upgraded
Nektar Therapeutics (NKTR) was upgraded to D from D- on 5/6/2016 due to a significant increase in the solvency index, valuation index and total return index. Debt to equity declined from 38.4 to -897.86.
Nektar Therapeutics (NKTR) was upgraded to D from D- on 5/6/2016 due to a significant increase in the solvency index, valuation index and total return index. Debt to equity declined from 38.4 to -897.86.
D
Sell
3/11/2016Downgrade
Nektar Therapeutics (NKTR) was downgraded to D- from D on 3/11/2016 due to a significant decline in the solvency index, volatility index and growth index. EBIT declined 7,108.11% from $419 to -$29.36M, debt to equity increased from 3.35 to 38.4, and earnings per share declined from -$0.0618 to -$0.4035.
Nektar Therapeutics (NKTR) was downgraded to D- from D on 3/11/2016 due to a significant decline in the solvency index, volatility index and growth index. EBIT declined 7,108.11% from $419 to -$29.36M, debt to equity increased from 3.35 to 38.4, and earnings per share declined from -$0.0618 to -$0.4035.
D
Sell
11/6/2015Downgrade
Nektar Therapeutics (NKTR) was downgraded to D from D+ on 11/6/2015 due to a substantial decline in the efficiency index and total return index. Net income declined 84.42% from -$52.66M to -$8.2M.
Nektar Therapeutics (NKTR) was downgraded to D from D+ on 11/6/2015 due to a substantial decline in the efficiency index and total return index. Net income declined 84.42% from -$52.66M to -$8.2M.
D
Sell
8/7/2015Downgrade
Nektar Therapeutics (NKTR) was downgraded to D+ from C on 8/7/2015 due to a significant decline in the growth index, volatility index and solvency index. Earnings per share declined from $0.25 to -$0.4, EBIT declined 200.99% from $43.04M to -$43.47M, and operating cash flow declined 174.64% from $63.31M to -$47.26M.
Nektar Therapeutics (NKTR) was downgraded to D+ from C on 8/7/2015 due to a significant decline in the growth index, volatility index and solvency index. Earnings per share declined from $0.25 to -$0.4, EBIT declined 200.99% from $43.04M to -$43.47M, and operating cash flow declined 174.64% from $63.31M to -$47.26M.
C
Hold
5/1/2015Upgraded
Nektar Therapeutics (NKTR) was upgraded to C from D on 5/1/2015 due to a significant increase in the growth index, efficiency index and solvency index. Total revenue increased 456.47% from $19.55M to $108.8M, debt to equity declined from 3.56 to 1.69, and total capital increased 24.78% from $169.98M to $212.1M.
Nektar Therapeutics (NKTR) was upgraded to C from D on 5/1/2015 due to a significant increase in the growth index, efficiency index and solvency index. Total revenue increased 456.47% from $19.55M to $108.8M, debt to equity declined from 3.56 to 1.69, and total capital increased 24.78% from $169.98M to $212.1M.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
